A carregar...
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
BACKGROUND: Guselkumab is an interleukin‐23 inhibitor indicated for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab. Long‐term efficacy comparisons of guselkumab and ustekinumab a...
Na minha lista:
| Publicado no: | Br J Dermatol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7496582/ https://ncbi.nlm.nih.gov/pubmed/31652347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18634 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|